ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - catype/medical-oncology/gastric-and-oesophageal/advanced-metastatic/her2-positive/first-line
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
Gastrointestinal (Upper) / Gastric and oesophageal - Advanced/metastatic / HER2-positive / First line
2
trial(s) found.
NCT06764875
Advanced
Phase 3
Recruiting
A Randomized, Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan Versus Trastuzumab, Chemotherapy, and Pembrolizumab for the
First Line
Treatment of HER2-positive Gastric Cancer (ARTEMIDE-Gastric01) (
D702AC00001
)
anti-ERBB2 antibody-drug conjugate
anti-ERBB2 monoclonal antibody
anti-PD-1 monoclonal antibody
bispecific PD-1/TIGIT antibody
Gastroesophageal junction adenocarcinoma
HER2-positive gastric cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06731478
Advanced
Phase 3
Recruiting
A Multicenter, Randomized, Open-Label, Phase 3 Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab Versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab as
First-Line
Treatment in Participants With Unresectable, Locally Advanced or Metastatic HER2-Positive Gastric Or Gastroesophageal Junction (GEJ) Cancer (Destiny-Gastric05) (
DS8201-724
)
anti-ERBB2 antibody-drug conjugate
anti-ERBB2 monoclonal antibody
anti-PD-1 monoclonal antibody
Cancer
Gastric cancer
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2500 - Wollongong - Wollongong Hospital
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3168 - Clayton - Monash Medical Centre
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (2)
Recruitment Country and State
NSW (2)
VIC (2)
WA (2)
QLD (1)
SA (1)
Phase
Phase 3 (2)
Trial Type
Advanced (2)
Cancer Therapy Class
ERBB2
100%
PD-1
100%
PD-1/PD-L1
100%
TIGIT
50%
Facility
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (1)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (1)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (1)
6150 - Murdoch - Fiona Stanley Hospital (1)
2065 - St Leonards - GenesisCare North Shore Private Hospital (1)
2500 - Wollongong - Wollongong Hospital (1)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (1)
3168 - Clayton - Monash Medical Centre (1)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (1)
5042 - Bedford Park - Flinders Medical Centre (1)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (1)
Cancer Type
Cancer
Gastric cancer
Gastroesophageal cancer
Gastrointestinal cancer
Solid tumour
Upper gastrointestinal cancer
Gastric adenocarcinoma
Gastric carcinoma
Gastroesophageal junction adenocarcinoma
HER2-positive gastric cancer
Oesophageal cancer
Thoracic cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy